Display options
Cite
Cardinal RN, Savulich G, Mann LM, et al. Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register. NPJ Schizophr. 2015;1:15035doi: 10.1038/npjschz.2015.35.
Cardinal, R. N., Savulich, G., Mann, L. M., & Fernández-Egea, E. (2015). Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register. NPJ schizophrenia, 115035. https://doi.org/10.1038/npjschz.2015.35
Cardinal, Rudolf N, et al. "Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register." NPJ schizophrenia vol. 1 (2015): 15035. doi: https://doi.org/10.1038/npjschz.2015.35
Cardinal RN, Savulich G, Mann LM, Fernández-Egea E. Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register. NPJ Schizophr. 2015 Oct 21;1:15035. doi: 10.1038/npjschz.2015.35. eCollection 2015. PMID: 27336041; PMCID: PMC4849458.
Copy Download .nbib Format: NLM
Share it on

NPJ Schizophr. 2015 Oct 21;1:15035. doi: 10.1038/npjschz.2015.35. eCollection 2015.

Association between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register.

NPJ schizophrenia

Rudolf N Cardinal, George Savulich, Louisa M Mann, Emilio Fernández-Egea

Affiliations

  1. Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge, Cambridge, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Elizabeth House, Fulbourn Hospital, Cambridge, UK.
  2. Behavioural and Clinical Neuroscience Institute, Department of Psychiatry, University of Cambridge , Cambridge, UK.
  3. Cambridgeshire and Peterborough NHS Foundation Trust, Elizabeth House, Fulbourn Hospital , Cambridge, UK.

PMID: 27336041 PMCID: PMC4849458 DOI: 10.1038/npjschz.2015.35

Abstract

BACKGROUND: The impact of psychotropic drug choice upon admissions for schizophrenia is not well understood.

AIMS: To examine the association between antipsychotic/antidepressant use and time in hospital for patients with schizophrenia.

METHODS: We conducted an observational study, using 8 years' admission records and electronically generated drug histories from an institution providing secondary mental health care in Cambridgeshire, UK, covering the period 2005-2012 inclusive. Patients with a coded ICD-10 diagnosis of schizophrenia were selected. The primary outcome measure was the time spent as an inpatient in a psychiatric unit. Antipsychotic and antidepressant drugs used by at least 5% of patients overall were examined for associations with admissions. Periods before and after drug commencement were compared for patients having pre-drug admissions, in mirror-image analyses correcting for overall admission rates. Drug use in one 6-month calendar period was used to predict admissions in the next period, across all patients, in a regression analysis accounting for the effects of all other drugs studied and for time.

RESULTS: In mirror-image analyses, sulpiride, aripiprazole, clozapine, and olanzapine were associated with fewer subsequent admission days. In regression analyses, sulpiride, mirtazapine, venlafaxine, and clozapine-aripiprazole and clozapine-amisulpride combinations were associated with fewer subsequent admission days.

CONCLUSIONS: Use of these drugs was associated with fewer days in hospital. Causation is not implied and these findings require confirmation by randomized controlled trials.

References

  1. J Clin Psychiatry. 2006 Dec;67(12):1942-7 - PubMed
  2. Pharmacopsychiatry. 1994 May;27(3):119-23 - PubMed
  3. Int Clin Psychopharmacol. 2006 Mar;21(2):99-103 - PubMed
  4. J Clin Psychiatry. 2011 Aug;72(8):1079-85 - PubMed
  5. Med Care. 2002 Aug;40(8):630-9 - PubMed
  6. Clin Schizophr Relat Psychoses. 2015 Summer;9(2):88-95 - PubMed
  7. J Clin Psychopharmacol. 2012 Oct;32(5):678-83 - PubMed
  8. PLoS Comput Biol. 2013;9(2):e1002854 - PubMed
  9. BMC Med Inform Decis Mak. 2013 Jul 11;13:71 - PubMed
  10. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007811 - PubMed
  11. Int Clin Psychopharmacol. 2012 May;27(3):159-64 - PubMed
  12. Psychopharmacol Bull. 1998;34(1):89-92 - PubMed
  13. Br J Psychiatry. 2015 May;206(5):357-9 - PubMed
  14. Braz J Med Biol Res. 1983 Dec;16(4):305-11 - PubMed
  15. BMJ. 2006 Jul 29;333(7561):224 - PubMed
  16. Psychiatry Res. 2011 Aug 15;188(3):315-9 - PubMed
  17. N Engl J Med. 2005 Sep 22;353(12 ):1209-23 - PubMed
  18. Psychopharmacol Bull. 1996;32(4):683-97 - PubMed
  19. Psychopharmacology (Berl). 1991;105(1):42-8 - PubMed
  20. Schizophr Bull. 2013 May;39(3):673-83 - PubMed
  21. Schizophr Res. 2011 Apr;127(1-3):93-9 - PubMed
  22. Pharmacopsychiatry. 2008 Jan;41(1):24-8 - PubMed
  23. Schizophr Bull. 2014 Mar;40(2):314-26 - PubMed
  24. Arch Gen Psychiatry. 2006 Oct;63(10):1079-87 - PubMed
  25. Lancet. 2013 Sep 14;382(9896):951-62 - PubMed
  26. Acta Psychiatr Scand Suppl. 1980;279:55-63 - PubMed
  27. J Clin Psychopharmacol. 2013 Aug;33(4):533-7 - PubMed
  28. J Psychopharmacol. 2002 Jun;16(2):169-75 - PubMed
  29. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008125 - PubMed
  30. Eur Neuropsychopharmacol. 2012 Mar;22(3):165-82 - PubMed
  31. Int J Geriatr Psychiatry. 2014 Dec;29(12):1249-54 - PubMed
  32. Curr Med Res Opin. 1997;14(1):1-20 - PubMed

Publication Types